ArticleTherapeutic advances in medical oncology2026
Microwave ablation for T1N0M0 papillary thyroid carcinoma located in the isthmus: a multicenter prospective cohort study with over 5-year follow-up.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04197960 (A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thermal ablation (TA) of papillary thyroid carcinoma (PTC) has been reported to have promising results. However, performing microwave ablation (MWA) on PTCs located in the isthmus remains controversial. Objectives: This study aimed to compare the feasibility, effectiveness, and safety of MWA for treating PTC in the isthmus and lateral lobes. Design: Prospective cohort study. Methods: In this study, between December 2019 and December 2020, patients with clinical T1N0M0 PTC who planned to receive MWA were enrolled from 12 hospitals. All tumors were evaluated by preoperative ultrasound and divided into isthmus-located tumors and lobe-located tumors. The patients were followed until 1 February 2025. The primary endpoints included technical success and disease-free survival. The secondary endpoints included treatment parameters, complications, and tumor shrinkage. Variables were compared between the two groups, and subgroup analysis was performed. Results: After exclusion, 652 patients (mean age, 43 years ± 11 (SD), 481 females) were included: 109 with PTC in the isthmus and 543 with PTC in the lateral lobes. One isthmic tumor terminated MWA, 108 versus 543 (mean tumor volume of 0.1 ml ± 0.1 vs 0.2 ml ± 0.2, Conclusion: MWA was feasible for T1N0M0 PTC in the isthmus and showed comparable efficacy in comparison with tumors in the lobes. Trial registration: NCT04197960.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.